JAK2 and myeloproliferative neoplasm: PRMT5 is overexpressed in primary MPN cells and PRMT5 inhibition has been shown to reverse the MPN phenotype in vivo in mouse models of both JAK2 V617F- and MPL W515L-mediated disease [82].